ConductScience.org, home
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)
API referenceFor AI assistants

Trial · NCT03374254

Participant flow36

How many started, completed or left each group, period by period.

1 to 20 of 36

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDCohort A Part 1: Pembrolizumab +Binimetinib 30 mg6
Overall StudySTARTEDCohort A Part 1: Pembrolizumab +Binimetinib 45 mg16
Overall StudySTARTEDCohort B Part 1: Pembrolizumab + mFOLFOX715
Overall StudySTARTEDCohort B Part 2: Pembrolizumab + mFOLFOX716
Overall StudySTARTEDCohort C Part 1: Pembrolizumab + mFOLFOX7 + Binimetinib 30 mg11
Overall StudySTARTEDCohort D Part 1: Pembrolizumab + FOLFIRI16
Overall StudySTARTEDCohort D Part 2: Pembrolizumab + FOLFIRI16
Overall StudySTARTEDCohort E Part 1: Pembrolizumab + FOLFIRI + Binimetinib 30 mg9
Overall StudySTARTEDCohort E Part 1: Pembrolizumab + FOLFIRI + Binimetinib 45 mg11
Overall StudyTreatedCohort A Part 1: Pembrolizumab +Binimetinib 30 mg6
Overall StudyTreatedCohort A Part 1: Pembrolizumab +Binimetinib 45 mg14
Overall StudyTreatedCohort B Part 1: Pembrolizumab + mFOLFOX715
Overall StudyTreatedCohort B Part 2: Pembrolizumab + mFOLFOX716
Overall StudyTreatedCohort C Part 1: Pembrolizumab + mFOLFOX7 + Binimetinib 30 mg11
Overall StudyTreatedCohort D Part 1: Pembrolizumab + FOLFIRI16
Overall StudyTreatedCohort D Part 2: Pembrolizumab + FOLFIRI16
Overall StudyTreatedCohort E Part 1: Pembrolizumab + FOLFIRI + Binimetinib 30 mg9
Overall StudyTreatedCohort E Part 1: Pembrolizumab + FOLFIRI + Binimetinib 45 mg11
Overall StudyCOMPLETEDCohort A Part 1: Pembrolizumab +Binimetinib 30 mg0
Overall StudyCOMPLETEDCohort A Part 1: Pembrolizumab +Binimetinib 45 mg0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03374254/flow

API referenceFor AI assistants